Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/jcm11123449
Keywords
systemic lupus erythematosus; anifrolumab; interferon; cutaneous lupus erythematosus
Categories
Funding
- Georg-August University Gottingen
Ask authors/readers for more resources
Systemic lupus erythematosus (SLE) is a clinically heterogeneous autoimmune disease with refractory cutaneous manifestations. This case report highlights the successful use of anifrolumab in a patient with predominant and refractory skin involvement. It also discusses the available clinical trial data of anifrolumab, suggesting its potential as a new therapeutic option for cutaneous manifestations of SLE.
Systemic lupus erythematosus (SLE) is a clinically heterogeneous autoimmune disease, and organ manifestations, such as lupus nephritis (LN) or skin disease, may be refractory to standard treatment. Therefore, new agents are required to allow for a more personalized therapeutic approach. Recently, several new therapies have been approved internationally, including voclosporine for LN and anifrolumab for moderately to severely active SLE. Here, we report a case of SLE with a predominant and refractory cutaneous manifestation despite combination treatment with glucocorticoids, hydroxychloroquine, mycophenolate mofetil, and belimumab, which had been present for more than 12 months. Belimumab was switched to anifrolumab, and the patient responded quickly after two infusions (eight weeks) with a reduction in the Cutaneous Lupus Assessment and Severity Index (CLASI) from 17 to 7. In addition, we review the available clinical trial data for anifrolumab with a focus on cutaneous outcomes. Based on phase II and III clinical trials investigating the intravenous administration, a consistent CLASI improvement was observed at 12 weeks. Interestingly, in a phase II trial of subcutaneous anifrolumab application, CLASI response was not different from placebo at 12 weeks but numerically different at 24 and 52 weeks, respectively. Thus, anifrolumab emerges as an attractive new therapeutic option suggesting a possible domain-based approach.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available